Neurizon Sets Out Funding Plan Ahead Of ALS Trial Results
NUZ: $0.062 -4.62% · MC: $48M
Neurizon’s investor presentation recaps its $4.3 million placement and proposed $2 million share purchase plan, alongside redemption of all remaining Obsidian convertible notes. The company says the funding is intended to strengthen its position ahead of anticipated HEALEY ALS Platform Trial results in late Q2 2027; the webinar is scheduled for today.

Comments